Discussion40Several trials evaluated a hydrocolloid dressingwith a traditional <strong>for</strong>m of care <strong>for</strong> the treatmentof pressure sores. 51–56 The combined OR showedthat there was a statistically significant increasein the number of wounds healed when treatedwith the hydrocolloid dressing. However, thetraditional treatments were poor comparators <strong>and</strong>are unlikely to be used with any frequency withinthe UK, thus the relevance <strong>for</strong> modern practice isunclear. The finding does however support currentnursing practice, which has eschewed gauze-baseddressings <strong>for</strong> the management of pressure sores.Studies directly comparing topical agents <strong>for</strong> thetreatment of pressure sores focused primarily onbiologically active agents. Most of these trials weretoo small to provide conclusive results <strong>and</strong> theirheterogeneity prevented pooling. At present theresults are highly inconsistent both within <strong>and</strong>between trials, <strong>and</strong> further, better-designedstudies with larger numbers are required.Trials comparing hydrocolloids with hydrogels,which also absorb exudate <strong>and</strong> maintain a moistwound surface, are equivocal. 46,47Although several trials have comparedalternative dressings with one another, nonehas shown a statistically significant differencebetween treatments.Leg ulcersThere were insufficient trials evaluating arterial legulcers to recommend any particular dressing <strong>for</strong>general use. It is interesting to note that the trialby Gibson <strong>and</strong> co-workers 69 was ab<strong>and</strong>oned due torapid withdrawal from the trial in patients allocatedto a knitted viscose dressing, though there was nodifference in the proportion of ulcers healed. 69Both mononuclear cultured cells 70 <strong>and</strong> ketanserin 71appeared to increase healing <strong>and</strong> these topicalagents may be worthy of further study.Only two trials in which the outcome was notreported by ulcer aetiology demonstrated a differencein healing rates. These trials suggested thattreatment with a growth factor, 81,82 or hyaluronicacid 84 were beneficial treatments, but furtherevaluations of these preparations in venous ulcersalone showed no difference in healing rates.Several trials evaluated a hydrocolloid dressing witha traditional dressing, usually paraffin-impregnatedor knitted viscose gauze, in venous leg ulcers.Combining these studies in a meta-analysis usinga r<strong>and</strong>om effects model showed that there wasno difference between the treatments <strong>for</strong> the proportionof ulcers healed. The two largest trials inthis analysis had ORs of 0.92 <strong>and</strong> 0.88 (odds ofhealing in the control). The smaller trials were,in general, more favourable <strong>for</strong> the hydrocolloid,suggesting that publication bias may be present.These results conflict with the evidence <strong>for</strong>pressure sore treatment where the trials suggestedthat hydrocolloid dressings are more effective thantraditional treatments. This apparent disparitybetween wound types may be related to methodof application used <strong>for</strong> the traditional treatment.A dry dressing, such as a knitted viscose dressing,will produce a moist wound environment whenused under a compression b<strong>and</strong>age, but may notwhen used over a pressure sore, depending on thesecondary dressings used. Wu <strong>and</strong> co-workers 137evaluated the moisture loss through compressionb<strong>and</strong>age(s) <strong>and</strong> dressings. They found that a drydressing covered with a multi-layer b<strong>and</strong>age stillhad a vastly reduced water vapour transmissionrate compared with the ulcer surface or thedressing alone. Hence the sum total of materialsapplied over a wound may influence the conditions<strong>for</strong> healing at the wound surface. Many of thetrials do not indicate whether secondary dressingswere used, <strong>and</strong> as secondary dressings influencethe interface conditions (e.g. temperature <strong>and</strong>moisture), then they may well influencehealing rates.There is currently insufficient evidence <strong>for</strong> eitherfoam or film dressings having a beneficial effecton leg ulcer healing.The one trial of a traditional zinc paste b<strong>and</strong>agewith a modern (alginate) dressing found the zincpaste to be more effective. However, this may havebeen confounded by the greater magnitude ofcompression beneath the paste (effectively amulti-layer b<strong>and</strong>age system). 138Comparisons between modern dressings(hydrocolloid dressing, lyophilised collagen,collagen sponge, dextranomer, hydropolymerdressing, alginate dressing, hydrocellular foam,or polyurethane foam) did not indicate thatany of the modern products was more effectivethan another.Comparisons between topical agents <strong>and</strong> controltreatments revealed only two preparations thatproduced a statistically significant difference inhealing rates. These were DMSO <strong>and</strong> allopurinol,
<strong>Health</strong> Technology Assessment 1999; Vol. 3: No. 17 (Pt 2)both of which are oxygen free radical scavengers<strong>and</strong> were evaluated in the same trial. This trialneeds to be replicated as the possibility that thecomparator (an inert powder) may have had adetrimental effect on healing cannot be ruled out.DMSO has also been found to be effective in thetreatment of diabetic foot ulcers <strong>and</strong> is worthy offurther investigation. 139Biologically active topical agents, cells ormembranes, were not found to be more effectivethan control dressings, such as paraffin gauze orculture medium. Similarly, growth factors were notdemonstrated to be more effective than the tissueculture medium alone. This is in contrast withevaluations in the treatment of diabetic foot ulcerswhere they have been shown to be effective. 139There may be two explanations <strong>for</strong> this.• There may be differences in microcirculatorypathology between diabetic <strong>and</strong> venous ulcers;the <strong>for</strong>mer being amenable to treatment bygrowth factor.• Growth factors are effective in the treatment ofvenous leg ulcers but the method of application<strong>and</strong>/or the power of the studies has resultedin a type 2 error. One striking difference in theapplication of growth factors to the two differentwound types is the amount of debridementper<strong>for</strong>med. During the treatment of diabeticfoot ulcers, the skin <strong>and</strong> wound are frequentlydebrided to remove dead tissue. 139 A bleedingwound bed may be prepared prior to the applicationof the growth factors. Sharp debridementis rarely per<strong>for</strong>med on venous leg ulcers <strong>and</strong>there was no pretreatment debridement in thetrials reported here. 127–130Comparisons between dressings <strong>and</strong> topical agentsindicated that a collagen dressing was preferableto the daily application of an antiseptic, while ahydrocolloid dressing healed more ulcers thanmagnesium paste. However, neither magnesiumpaste nor topical antiseptic are widely used todayin the UK suggesting that the generalisability ofthese results is limited.Publication biasFunnel plots indicated that publication bias may bepresent <strong>for</strong> trials that compared hydrocolloids withtraditional treatments. Asymmetry of the funnelplot can result from: 140• publication bias• language bias• multiple publication bias• poor methodological design amongstsmaller studies• true heterogeneity (i.e. ES differs accordingto study size due to intensity of intervention)• chance.It is inevitable that despite searching <strong>for</strong>unpublished studies this review relies heavilyon published trials. There is at present nost<strong>and</strong>ardised method to ensure a comprehensivesearch <strong>for</strong> unpublished data. Careful screeningof all included studies was undertaken to reducethe potential <strong>for</strong> multiple studies <strong>and</strong> the searchstrategy was designed to improve sensitivity <strong>for</strong>non-English publications. True heterogeneity isunlikely to have influenced publication bias asthe largest studies did not employ interventionsthat differed from the smaller ones. The almostuni<strong>for</strong>m direction of the bias suggests that itwas not purely a chance result. Poor methodologicaldesign of the smaller studies could beresponsible <strong>for</strong> skewing the funnel plot; thesmaller effect size demonstrated in the larger,more rigorous studies may indicate this.However, publication bias remains the mostlikely cause of asymmetry. 140 This type of biasmay result from restrictive practices that preventall the evaluative research entering the publicdomain. There are several reasons why publicationbias could skew the data, two of the mostcommon causes are:• pharmaceutical companies are unlikely tofavour the publication of sponsored trialswhere a result favoured the st<strong>and</strong>ard, genericalternative. Such suppression of publicationis more likely <strong>for</strong> small, under-poweredstudies than <strong>for</strong> large, multicentre trials• journal editors or researchers may notfavour publication of small studies with‘null’ (i.e. non-significant) results, particularlyif they have been preceded by largerstudies that indicated a positive benefit <strong>for</strong>an intervention. This does not appear tobe the case here as the majority of trialswere non-significant.Analysis of the funnel plot by date of publicationsuggests there is little evidence that the year ofpublication was related to the outcome reported.In other words, commercial considerations maybe the causative factor of asymmetry (Figure 24).Hydrocolloid dressings were amongst the firstmodern dressings to be intensively marketed <strong>and</strong>companies would be unlikely to publish researchwith negative results. A similar publication bias41
- Page 1 and 2: Health Technology Assessment 1999;
- Page 3 and 4: Systematic reviews of wound careman
- Page 7: Health Technology Assessment 1999;
- Page 10 and 11: Executive summarythan either an alg
- Page 12 and 13: Introduction2sores) or due to under
- Page 14 and 15: Introduction4healing rates are low
- Page 17 and 18: Health Technology Assessment 1999;
- Page 19: Health Technology Assessment 1999;
- Page 22 and 23: ResultsMacfie & McMahon, 1980 34Com
- Page 24 and 25: ResultsLe Vasseur & Helme, 1991 40C
- Page 26 and 27: ResultsMustoe et al., 1994 43Compar
- Page 28 and 29: ResultsSayag et al., 1996 49Compari
- Page 30 and 31: ResultsOleske et al., 1986 57Compar
- Page 32 and 33: ResultsBrod et al., 1990 66Comparis
- Page 34 and 35: ResultsMoffatt et al., 1992 88Compa
- Page 36 and 37: ResultsArnold et al., 1994 99Compar
- Page 38 and 39: Results28healed under a lyophilised
- Page 40 and 41: ResultsZuccarelli, 1993 113Comparis
- Page 42 and 43: ResultsHolzinger et al., 1994 70Com
- Page 44 and 45: ResultsWerner-Schlenzka & Kuhlmann,
- Page 46 and 47: ResultsTosti & Veronesi, 1983 132Co
- Page 48 and 49: ResultsSix trials evaluated cost-ef
- Page 52 and 53: Discussionmay also exist for other
- Page 54 and 55: Conclusionssupport, promote collabo
- Page 57 and 58: Health Technology Assessment 1999;
- Page 59 and 60: Health Technology Assessment 1999;
- Page 61 and 62: Health Technology Assessment 1999;
- Page 63 and 64: Health Technology Assessment 1999;
- Page 65: Health Technology Assessment 1999;
- Page 69 and 70: Health Technology Assessment 1999;
- Page 71 and 72: Health Technology Assessment 1999;
- Page 73 and 74: Health Technology Assessment 1999;
- Page 75 and 76: Health Technology Assessment 1999;
- Page 77 and 78: Health Technology Assessment 1999;
- Page 79 and 80: Health Technology Assessment 1999;
- Page 81: Health Technology Assessment 1999;
- Page 84 and 85: Appendix 6TABLE 7 contd Dressings c
- Page 87 and 88: Health Technology Assessment 1999;
- Page 89 and 90: Health Technology Assessment 1999;
- Page 91 and 92: Health Technology Assessment 1999;
- Page 93 and 94: Health Technology Assessment 1999;
- Page 95 and 96: Health Technology Assessment 1999;
- Page 97 and 98: Health Technology Assessment 1999;
- Page 99 and 100: Health Technology Assessment 1999;
- Page 101:
Health Technology Assessment 1999;
- Page 104 and 105:
Appendix 8TABLE 16 Topical preparat
- Page 106 and 107:
Appendix 9TABLE 17 contd Dressings
- Page 108 and 109:
Appendix 9TABLE 18 contd Comparison
- Page 110 and 111:
Appendix 9TABLE 19 contd Topical pr
- Page 112 and 113:
Appendix 10TABLE 21 contd Dressings
- Page 114 and 115:
Appendix 10TABLE 21 contd Dressings
- Page 116 and 117:
Appendix 10TABLE 21 contd Dressings
- Page 118 and 119:
Appendix 10TABLE 22 Comparisons of
- Page 120 and 121:
Appendix 10TABLE 22 contd Compariso
- Page 122 and 123:
Appendix 10TABLE 23 Topical prepara
- Page 124 and 125:
Appendix 10TABLE 23 contd Topical p
- Page 126 and 127:
Appendix 10TABLE 23 contd Topical p
- Page 128 and 129:
Appendix 10TABLE 24 contd Topical p
- Page 130 and 131:
Appendix 10TABLE 25 contd Topical p
- Page 132 and 133:
Appendix 10TABLE 26 contd Compariso
- Page 134 and 135:
Appendix 11124TABLE 27 Summary of c
- Page 136 and 137:
Appendix 11TABLE 28 Differences in
- Page 138 and 139:
Health Technology Assessment panel
- Page 140 and 141:
Health Technology Assessment panel
- Page 142 and 143:
HTA Commissioning BoardCurrent memb